BIOMAT Database Logo BIOMAT Database Logo

In vitro and in vivo studies to prevent hyperacute rejection. 1996

S Miyagawa, and M Mikata, and H Matsuda, and M Ikawa, and M Okabe, and S Nagasawa, and M Matsumoto, and T Seya, and R Shirakura
Division of Organ Transplantation, Osaka University Medical School, Japan.

UI MeSH Term Description Entries
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003169 Complement Inactivator Proteins Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors. Complement Cytolysis Inhibiting Proteins,Complement Cytolysis Inhibitor Proteins,Complement Inactivating Proteins,Serum Complement Inactivators,Complement Inactivators, Serum,Inactivating Proteins, Complement,Inactivator Proteins, Complement,Inactivators, Serum Complement,Proteins, Complement Inactivating,Proteins, Complement Inactivator
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Miyagawa, and M Mikata, and H Matsuda, and M Ikawa, and M Okabe, and S Nagasawa, and M Matsumoto, and T Seya, and R Shirakura
In vitro studies of hyperacute rejection of xenografts.
January 1972, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes,
S Miyagawa, and M Mikata, and H Matsuda, and M Ikawa, and M Okabe, and S Nagasawa, and M Matsumoto, and T Seya, and R Shirakura
Inability of thoracic duct drainage to prevent hyperacute rejection.
August 1983, Transplantation,
S Miyagawa, and M Mikata, and H Matsuda, and M Ikawa, and M Okabe, and S Nagasawa, and M Matsumoto, and T Seya, and R Shirakura
In vitro studies on the mechanism of hyperacute xenograft rejection.
March 1971, Transplantation proceedings,
S Miyagawa, and M Mikata, and H Matsuda, and M Ikawa, and M Okabe, and S Nagasawa, and M Matsumoto, and T Seya, and R Shirakura
Potential of an injectable polymer to prevent hyperacute rejection of ex vivo perfused porcine lungs.
September 2006, Transplantation,
S Miyagawa, and M Mikata, and H Matsuda, and M Ikawa, and M Okabe, and S Nagasawa, and M Matsumoto, and T Seya, and R Shirakura
Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection. An in vivo and in vitro evaluation.
November 1995, Transplantation,
S Miyagawa, and M Mikata, and H Matsuda, and M Ikawa, and M Okabe, and S Nagasawa, and M Matsumoto, and T Seya, and R Shirakura
In vivo and in vitro study of hyperacute rejection mechanism of renal discordant xenograft.
February 1991, Transplantation proceedings,
S Miyagawa, and M Mikata, and H Matsuda, and M Ikawa, and M Okabe, and S Nagasawa, and M Matsumoto, and T Seya, and R Shirakura
Use of donor serum to prevent passive transfer of hyperacute rejection.
July 1994, The Journal of surgical research,
S Miyagawa, and M Mikata, and H Matsuda, and M Ikawa, and M Okabe, and S Nagasawa, and M Matsumoto, and T Seya, and R Shirakura
Hyperacute rejection in heart allografts. Case studies.
January 1991, Pathology, research and practice,
S Miyagawa, and M Mikata, and H Matsuda, and M Ikawa, and M Okabe, and S Nagasawa, and M Matsumoto, and T Seya, and R Shirakura
Hyperacute rejection models: ex vivo xenoperfusion systems.
January 1999, Transplantation proceedings,
S Miyagawa, and M Mikata, and H Matsuda, and M Ikawa, and M Okabe, and S Nagasawa, and M Matsumoto, and T Seya, and R Shirakura
[Further in-vitro studies on the mechanism of hyperacute xenogenic rejection reaction (HXAR)].
January 1975, Langenbecks Archiv fur Chirurgie,
Copied contents to your clipboard!